Show simple item record

dc.contributor.authorZimmermann, Petra
dc.contributor.authorPerrett, Kirsten P
dc.contributor.authorBerbers, Guy
dc.contributor.authorCurtis, Nigel
dc.date.accessioned2019-03-22T09:17:07Z
dc.date.available2019-03-22T09:17:07Z
dc.date.issued2019-02-22
dc.identifier.issn1468-2044
dc.identifier.pmid30796020
dc.identifier.doi10.1136/archdischild-2018-316254
dc.identifier.urihttp://hdl.handle.net/10029/622903
dc.description.abstractDespite immunisation, antibiotics and intensive care management, infection with We measured pneumococcal antibody concentrations to all 13 antigens included in the 13-valent pneumococcal conjugate vaccine (PCV13) after immunisation with a 3+0 schedule in 91 infants at 7 months and in 311 infants at 13 months of age. The geometric mean concentrations (GMCs) and the proportion of infants with an antibody concentration above the standard threshold correlate of protection (seroprotection rate) were calculated at both time points. At 7 months of age, GMCs varied between 0.52 µg/mLand 11.52 µg/mL, and seroprotection rates varied between 69% and 100%. At 13 months of age, GMCs had decreased to between 0.22 µg/mLand 3.09 µg/mL, with the lowest responses against serotype 4, followed by 19A, 3, 6B and 23F. Seroprotection rates at 13 months of age were below 90% for most serotypes, with the lowest rates for serotype 4 (23%) followed by 19A (50%), 23F (61%) and 6B (64%). Our study shows that at 13 months of age, many infants vaccinated with a 3+0 schedule have pneumococcal antibody concentrations below the standard threshold correlate of protection. To optimise protection against pneumococcal disease through early childhood and to improve antibody persistence and indirect protective effects, immunisation schedules with booster doses might be necessary.en_US
dc.language.isoenen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjecthumoralen_US
dc.subjectimmunoglobulinen_US
dc.subjectpneumococcusen_US
dc.subjectprevenaren_US
dc.subjectstreptococcus pneumoniaeen_US
dc.subjecttitreen_US
dc.subjectvaccineen_US
dc.titlePersistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine.en_US
dc.typeArticleen_US
dc.identifier.journalArch Dis Child 2019; 104(7):680-84en_US
dc.source.journaltitleArchives of disease in childhood


This item appears in the following Collection(s)

Show simple item record